Testosterone enanthate is an injectable depot ester of testosterone. Current U.S. labelling describes prescription replacement therapy for conditions associated with deficient or absent endogenous testosterone, not a general performance or anti-ageing treatment.

Established. Review the research and limitations before relying on this record.

Hydrolysis releases testosterone, which acts through androgen receptors; testosterone can also be metabolised to dihydrotestosterone and estradiol in responsive tissues.

The cited intramuscular product is a sesame-oil solution, while other approved enanthate products use other routes and delivery systems. Pharmacokinetic values are formulation-specific and should not be treated as interchangeable simply because the ester name matches.

The evidence base and U.S. label are for testosterone replacement in confirmed primary or hypogonadotropic hypogonadism. The label states that safety and effectiveness for age-related hypogonadism have not been established.

The label warns about polycythaemia, venous thromboembolism, prostate effects, oedema, lipid changes and abuse or dependence. It also notes that non-prescribed testosterone, often used with other anabolic-androgenic steroids, has been abused by athletes and bodybuilders. Anabolic agents are prohibited in sport under the WADA list.

“Oil” is informal gym shorthand, not a pharmacological category. This record describes the cited regulated formulation or animal-drug status only; it is not a protocol, a product-quality endorsement, or a recommendation. Human and veterinary products are not interchangeable.